New Edge Advisors, LLC Recursion Pharmaceuticals, Inc. Transaction History
New Edge Advisors, LLC
- $15 Billion
- Q3 2024
A detailed history of New Edge Advisors, LLC transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, New Edge Advisors, LLC holds 5,460 shares of RXRX stock, worth $36,909. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,460
Previous 2,600
110.0%
Holding current value
$36,909
Previous $19,000
84.21%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding RXRX
# of Institutions
286Shares Held
242MCall Options Held
1.35MPut Options Held
2.32M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl32.8MShares$222 Million2.05% of portfolio
-
Baillie Gifford & CO25.2MShares$171 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA24.3MShares$164 Million0.0% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$117 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA15.4MShares$104 Million1.41% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.22B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...